Rubicon Research的IPO的首次投资猛增27.8%,其动力是强劲的需求和坚实的财政。 Rubicon Research's IPO surged 27.8% on debut, fueled by strong demand and solid financials.

2025年10月16日, Rubicon Research在印度证券交易所开业, 股票开放率超过IPO485的27.8%, 在BSE和NSE上交易620美分。 Rubicon Research made a strong debut on India’s stock exchanges on October 16, 2025, with shares opening 27.8% above the IPO price of ₹485, trading at ₹620 on both the BSE and NSE. 由于有资格的机构买家和非机构投资者对此有强烈兴趣, 创投价值1,377.5亿卢比的IPO获得了巨大的需求, 总体上订阅了103.9倍. The ₹1,377.5 crore IPO saw overwhelming demand, subscribing 103.9 times overall, driven by strong interest from qualified institutional buyers and non-institutional investors. 该公司是一家以美国市场为重点的专业制药厂,报告25财政年度金融业绩良好,收入增长49%,利润高。 The company, a specialty pharmaceutical manufacturer focused on the U.S. market, reported strong financial performance in FY25, with 49% revenue growth and high profitability. 新问题的收益将用于减债、获取和增长举措。 Proceeds from the fresh issue will be used for debt reduction, acquisitions, and growth initiatives.